FORT COLLINS, Colo.,
Aug. 11, 2021 /PRNewswire/ --
Cytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical
company creating next-generation immune therapies that focus on
immune restoration and homeostasis, today announced that the
company will participate at the Empowering the Kingdom through
Business Conference hosted by the Liberty
University School of Business on August 10-12, 2021. Cytocom President and CEO,
Mike K. Handley, will participate
live as a featured panelist in the Healthcare Breakout session
moderated by Dean Joseph Johnson on
August 11, 2021.
About Cytocom
Cytocom, Inc. is a clinical-stage biopharmaceutical company
developing novel immunotherapies targeting autoimmune,
neutropenia/anemia, emerging viruses and cancers based on a
proprietary platform designed to rebalance the body's immune system
and restore homeostasis. The company also has one of the largest
platforms of toll-like immune receptors (TLR4, TLR5 and TLR9) in
the biopharmaceutical industry, addressing conditions such as
radiation sickness and cancer treatment side effects. Cytocom is
developing therapies designed to elicit directly within patients a
robust and durable response of antigen-specific killer T-cells and
antibodies, thereby activating essential immune defenses against
autoimmune, inflammatory, infectious diseases, and cancers.
Specifically, Cytocom has several clinical-stage development
programs for Crohn's disease, pancreatic cancer, COVID-19 in
addition to expansion to fibromyalgia and multiple sclerosis. To
learn more about Cytocom, Inc., please visit www.cytocom.com.
Forward Looking Statements:
This press release contains forward-looking statements that
involve risks and uncertainties. All statements other than
statements of current or historical fact contained in this press
release, including statements regarding our future financial
position, business strategy, new products, budgets, liquidity, cash
flows, projected costs, regulatory approvals, the impact of any
laws or regulations applicable to the company, and plans and
objectives of management for future operations, are forward-looking
statements. The words "anticipate," "believe," "continue,"
"should," "estimate," "expect," "intend," "may," "plan," "project,"
"will," and similar expressions, as they relate to us, are intended
to identify forward-looking statements. We have based these
forward-looking statements on the current expectations about future
events held by management. While we believe these expectations are
reasonable, such forward-looking statements are inherently subject
to risks and uncertainties, many of which are beyond our control.
The company's actual future results may differ materially from
those discussed here for various reasons. The company discusses
many of these risks under the heading "Risk Factors" in the proxy
statement/prospectus filed with the SEC on June 10, 2021, as updated by the company's other
filings with the SEC. Factors that may cause such differences
include, but are not limited to, the outcome of any legal
proceedings that have been or may be instituted against the company
related to the merger between Cytocom and Cleveland BioLabs;
unexpected costs, charges or expenses resulting from the merger;
our need for additional financing to meet our business objectives;
our history of operating losses; our ability to successfully
develop, obtain regulatory approval for, and commercialize our
products in a timely manner; our plans to research, develop and
commercialize our product candidates; our ability to attract
collaborators with development, regulatory and commercialization
expertise; our plans and expectations with respect to future
clinical trials and commercial scale-up activities; our reliance on
third-party manufacturers of our product candidates; the size and
growth potential of the markets for our product candidates, and our
ability to serve those markets; the rate and degree of market
acceptance of our product candidates; regulatory requirements and
developments in the United States,
the European Union and foreign countries; the performance of our
third-party suppliers and manufacturers; the success of competing
therapies that are or may become available; our ability to attract
and retain key scientific or management personnel; our historical
reliance on government funding for a significant portion of our
operating costs and expenses; government contracting processes and
requirements; the exercise of significant influence over our
company by our largest individual stockholder; the impact of
the novel coronavirus ("COVID-19") pandemic on our business,
operations and clinical development; the geopolitical
relationship between the United
States and the Russian
Federation as well as general business, legal, financial and
other conditions within the Russian
Federation; our ability to obtain and maintain intellectual
property protection for our product candidates; our potential
vulnerability to cybersecurity breaches; and other factors
discussed in our SEC filings, including our Annual Report on Form
10-K for the year ended December 31,
2020 and the risk factors discussed under the heading
"Risk Factors" in the proxy statement/prospectus the company filed
in connection with the merger on June 10,
2021.
Given these uncertainties, you should not place undue
reliance on these forward-looking statements. The forward-looking
statements included in this press release are made only as of the
date hereof. We do not undertake any obligation to update any such
statements or to publicly announce the results of any revisions to
any of such statements to reflect future events or
developments.
Contacts:
Cytocom, Inc.
Nichol
Ochsner
Senior V.P. Investor Relations and Corporate Communications
(732) 754-2545
nichol.ochsner@cytocom.com
Tiberend Strategic Advisors,
Inc.
Maureen
McEnroe, CFA (Investors)
(212) 375-2664
mmcenroe@tiberend.com
Johanna Bennett (Media)
(212) 375-2686
jbennett@tiberend.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cytocom-inc-announces-participation-at-liberty-universitys-empowering-the-kingdom-through-business-conference-301352929.html
SOURCE Cytocom Inc.
